Bioequivalence of mirabegron 50 mg extended release Tablet [Design Issues]

posted by jishnu – India, 2022-08-04 11:09 (571 d 09:10 ago) – Posting: # 23201
Views: 2,311


Why the study of 25mg strength under fed condition dose not need for mirabegron???

Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5[Helmut]

Complete thread:

UA Flag
 Admin contact
22,912 posts in 4,806 threads, 1,635 registered users;
26 visitors (0 registered, 26 guests [including 4 identified bots]).
Forum time: 19:19 CET (Europe/Vienna)

[…] an inappropriate study design is incapable of answering
a research question, no matter how careful the subsequent
methodology, conduct, analysis, and interpretation:
Flawless execution of a flawed design achieves nothing worthwhile.    J. Rick Turner

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz